行情

MDGL

MDGL

新泰医药
NASDAQ

实时行情|Nasdaq Last Sale

63.57
-1.69
-2.59%
盘后: 63.57 0 0.00% 16:31 01/21 EST
开盘
64.73
昨收
65.26
最高
66.23
最低
63.02
成交量
24.22万
成交额
--
52周最高
142.62
52周最低
63.02
市值
10.87亿
市盈率(TTM)
-4.3392
分时
5日
1月
3月
1年
5年
Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer
CONSHOHOCKEN, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announced today that Dr. Dominic F. Labriola has joined Madr...
GlobeNewswire · 01/10 13:00
Lab Notes: NRx seeks patent for Covid-19 therapy; Baudax Bio raises $4.2M
Philadelphia-area life sciences news this week includes updates on a company seeking a patent for its Covid-19 therapy, a private stock sale, and a Temple University spinout publishing its study findings on a potential treatment for NASH.
American City Business Journals · 01/07 17:29
Madrigal rises as H. C. Wainwright defends after delay in liver disease trial
Madrigal Pharmaceuticals (MDGL +4.2%) continues to rise despite its pre-market announcement over a delayed timeline for a topline data readout from its Phase 3 MAESTRO-NAFLD trial for resmetirom in patients
Seekingalpha · 2021/12/30 16:26
Madrigal expects delay in results from phase 3 trial of liver drug resmetirom
Madrigal Pharmaceuticals (NASDAQ:MDGL) said topline results from a phase 3 trial called MAESTRO-NAFLD-1 of resmetirom in patients with non-alcoholic fatty liver disease, presumed Non-alcoholic steatohepatitis (NASH), is now expected in January
Seekingalpha · 2021/12/30 13:34
Madrigal Provides Update On Timeline For Topline Results From The Phase 3 MAESTRO-NAFLD-1 Clinical Trial Of Resmetirom
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides an update on MAESTRO-NAFLD-1, its 52-week Phase 3 multi-center, double-blind, randomized, placebo-controlled study of resmetirom in patients with
Benzinga · 2021/12/30 13:05
Top 10 Stock Picks of Billionaire Nicholas Pritzker
In this article, we discuss the top 10 stock picks of billionaire Nicholas Pritzker. If you want to skip our detailed analysis of Pritzker’s history, investment philosophy, and hedge fund performance, go directly to Top 5 Stock Picks of Billionaire Nichola...
Insider Monkey · 2021/12/22 14:16
高盛公布生物制药板块最新潜在并购名单,最高溢价516%!
高盛公布生物制药板块最新潜在并购名单,最高溢价516%!
智通财经 · 2021/12/20 06:07
Alnylam, Crispr Therapeutics among Goldman's biopharma M&A targets for 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have
Seekingalpha · 2021/12/19 14:00
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解MDGL最新的财务预测,通过MDGL每股收益,每股净资产,每股现金流等数据分析新泰医药近期的经营情况,然后做出明智的投资选择。
分析师评级

13位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

30.77%强力推荐
61.54%买入
0.00%中性
7.69%落后大盘
0.00%卖出
目标价格预测
分析师预测MDGL价格均价为174.20,最高价位220.00,最低价为131.00。
最高220.00
均价174.20
最低131.00
现价63.57
EPS
实际EPS
预期EPS
-3.12-2.34-1.56-0.78
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 196
机构持股: 1,158.22万
持股比例: 67.74%
总股本: 1,709.71万
类型机构数股数
增持
48
101.20万
建仓
9
12.66万
减持
41
59.32万
平仓
26
80.51万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-1.82%
制药与医学研究
-1.11%
高管信息
Chairman/Chief Executive Officer/Director
Paul Friedman
Chief Financial Officer
Alex Howarth
Corporate Executive/Director
Rebecca Taub
Senior Vice President/General Counsel
Brian Lynch
Senior Vice President
Dominic Labriola
Senior Vice President
Remy Sukhija
Lead Director/Independent Director
Frederick Craves
Independent Director
Kenneth Bate
Independent Director
James Daly
Independent Director
Keith Gollust
Independent Director
Richard Levy
Independent Director
David Milligan
暂无数据
MDGL 简况
Madrigal Pharmaceuticals Inc是一家临床阶段的生物制药公司。该公司专注于治疗心血管、代谢和肝脏疾病的候选药物的开发和商业化。该公司的主要候选产品MGL-3196(resmetirom)是一种肝脏导向的选择性甲状腺激素受体-β(THR-β)激动剂,用于治疗非酒精性脂肪性肝炎(NASH)和杂合子家族性高胆固醇血症(HeFH)。其产品线还包括用于治疗NASH和HeFH的MGL-3745。

微牛提供Madrigal Pharmaceuticals Inc(NASDAQ-MDGL)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的MDGL股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易MDGL股票基本功能。